Global Anticoagulants Market to Spike to Over $24 Billion by 2019

Tuesday 16 April 2013, Amsterdam

This newly published “New Oral Anticoagulants Markets” report that the global anticoagulants market will spike to over $24 billion by 2019.
    
Anticoagulants can be categorized into five main modalities: low molecular weight heparins (LMWHs), herapins, warfarin, direct thrombin inhibitors (DTIs) and factor Xa inhibitors. The U.S. anticoagulants market, which encompasses over 60% of the global market for anticoagulants, will grow from $7.06 billion in 2012 to $15.32 billion in 2019 as it shifts from being monopolized by a single injectable anticoagulant, warfarin, to once-daily oral anticoagulants.

The “New Oral Anticoagulants Markets” report covers:

• Dabigatran (Pradaxa)
• Rivaroxaban (Xarelto)
• Eliquis (Apixaban)
• Edoxaban
• Betrixaban
• Antiplatelets
• Clotting Assays
• Cardiovascular Diseases
• Cardiac Arrhythmia
• Coronary Artery Disease
• Myocardial Infarction
• Heart Valve Replacement
• Deep Vein Thrombosis (DVT)

    
The “New Oral Anticoagulants Markets” report examines companies manufacturing anticoagulant equipment and supplies in the world.

Companies covered include:

• Akers,
• Anthera,
• ARYx,
• AstraZeneca,
• Boehringer Ingelheim,
• Cipla,
• Daiichi Sankyo,
• Eisai,
• Eli Lilly,
• Genentech,
• GlaxoSmithKline,
• Medicines Company,
• Medicure,
• Merck,
• Novartis,
• Ortho-McNeil,
• Pfizer,
• Pharmion,
• Portola and Sanofi.